Expand all sections

Insuline Icodec

Extended indication Type 1 en type 2 diabetes
Therapeutic value Possible benefit in ease of use
Registration phase Clinical trials

Product

Active substance Insuline Icodec
Domain Metabolism and Endocrinology
Reason of inclusion New medicine (specialité)
Main indication Diabetes
Extended indication Type 1 en type 2 diabetes
Manufacturer Novo Nordisk
Portfolio holder Novo Nordisk
Mechanism of action Insulin preparation
Route of administration Subcutaneous
Therapeutical formulation Injection
Budgetting framework Extramural (GVS)
Additional remarks Eenmaal wekelijkse dosering

Registration

Registration route Centralised (EMA)
ATMP No
Submission date 2023
Expected Registration 2024
Orphan drug No
Registration phase Clinical trials

Therapeutic value

Therapeutic value Possible benefit in ease of use
Frequency of administration 1 times a week
References NCT04880850; NCT04848480

Expected patient volume per year

References Gipdatabank
Additional remarks In 2016 waren er 446.462 gebruikers van insuline (totaal van 12 verschillende producten).

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.